Dr. Michael J. Mauro, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Geisel School of Medicine at Dartmouth (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 207
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Geisel School of Medicine at Dartmouth
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OR license MD22694
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Msk Bergen (255 clinicians)
- Memorial Hematology Lymphoma Group (216 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 207
- Services billed
- 638
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 223 | 126 |
| Established patient office or other outpatient visit, 30-39 minutes | 126 | 92 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 71 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 41 | 41 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 38 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 113 |
| Hydroxyurea Other prescribers in New York, NY | 100 |
| Allopurinol Other prescribers in New York, NY | 57 |
| Scemblix (asciminib hydrochloride) | 54 |
| Ojjaara (momelotinib dihydrochloride) | 39 |
| Sprycel (dasatinib) | 37 |
| Vonjo (pacritinib citrate) | 24 |
| Imatinib Mesylate | 17 |
| Pegasys (peginterferon alfa-2a) | 16 |
| Bosulif (bosutinib) | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 10 payments worth $25,603 in total to this clinician.
| Novartis Pharma AG | $14,038 |
|---|---|
| Novartis Pharmaceuticals Corporation | $8,520 |
| Pfizer Inc. | $2,670 |
| Takeda Pharmaceuticals U.S.A., Inc. | $375 |
| Consulting Fee | $14,203 |
|---|---|
| Travel and Lodging | $8,512 |
| Compensation for services other than consulting (speaking, faculty) | $2,670 |
| Food and Beverage | $217 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharma AG Jun 14, 2025 | Travel and Lodging SCEMBLIX · Oncology · travel to Milan, Italy · in-kind | $7,795 |
| Novartis Pharmaceuticals Corporation May 29, 2025 | Consulting Fee | $5,040 |
| Novartis Pharma AG Mar 3, 2025 | Consulting Fee SCEMBLIX · Oncology | $4,400 |
| Novartis Pharmaceuticals Corporation Jun 26, 2025 | Consulting Fee | $3,360 |
| Pfizer Inc. Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) BOSULIF · METABOLIC DISEASE;ONCOLOGY | $2,670 |
| Novartis Pharma AG Jun 14, 2025 | Consulting Fee SCEMBLIX · Oncology · in-kind | $1,028 |
| Novartis Pharma AG Jun 14, 2025 | Travel and Lodging SCEMBLIX · Oncology · travel to Milan, Italy · in-kind | $717 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 25, 2025 | Consulting Fee | $375 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $5,988,940 in research payments for these studies, mostly to the institutions running them.
- An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.